skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry

Abstract

Purpose: To investigate changes in quality of life (QoL) after permanent prostate brachytherapy and to correlate these changes with postimplant dosimetry based on magnetic resonance (MR) images. Methods and Materials: For this study, 127 patients with low-stage prostate cancer and treated with brachytherapy received a QoL questionnaire at five time points: before treatment and at 4 weeks, 6 months, 1 year, and 2 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer (EORTC) core questionnaire, the tumor-specific EORTC prostate cancer module, and the American Urological Association symptom index. Postimplant dosimetry was based on registered T1 spin echo transversal, T2 turbo spin echo transversal, and T2 turbo spin echo sagittal MR images and CT images taken 4 weeks after implantation of the iodine-125 seeds. Calculated parameters were prostate volume, prostate volume receiving 100% (V{sub 100}) and 150% (V{sub 150}) dose, dose to 90% of the prostate volume (D{sub 90}), maximum dose in 1-, 2-, and 5-cm{sup 3} rectum volume, distance between prostate and anterior rectum wall, and the maximum dose in 1%, 2%, and 5% urethra volume. Analysis of variance for repeated measures was used for comparison of themore » means of all variables in the different questionnaires. Linear regression analysis (stepwise) was used to investigate the correlations between QoL parameters and dosimetry parameters. Results: On average, only the QoL at 4 weeks after implant was significantly different from (worse than) the QoL at the other time points. Regression analysis showed a significant correlation between changes in bowel problems and the maximum dose in 2-cm{sup 3} rectum volume, between changes in urinary symptoms and prostate volume, and between changes in urinary problems and the D{sub 90} value of the prostate. Conclusions: The QoL for patients with permanent prostate implants was worse in the first months after treatment but returned to baseline values 1 year after implant. Significant correlations were found between dose distribution and QoL.« less

Authors:
 [1];  [2];  [2];  [2];  [2]
  1. Department of Radiotherapy, University Medical Center Utrecht, Utrecht (Netherlands). E-mail: marionvangellekom@yahoo.com
  2. Department of Radiotherapy, University Medical Center Utrecht, Utrecht (Netherlands)
Publication Date:
OSTI Identifier:
20702192
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 63; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2005.03.046; PII: S0360-3016(05)00581-X; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BRACHYTHERAPY; CARCINOMAS; COMPUTERIZED TOMOGRAPHY; DOSIMETRY; IMAGES; IODINE 125; PATIENTS; PROSTATE; RADIATION DOSES; RADIATION SOURCE IMPLANTS; RECTUM; SPIN ECHO; SYMPTOMS; URINARY TRACT

Citation Formats

Gellekom, Marion van, Moerland, Marinus A., Vulpen, Marco van, Wijrdeman, Harm K., and Battermann, Jan J. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. United States: N. p., 2005. Web. doi:10.1016/j.ijrobp.2005.03.046.
Gellekom, Marion van, Moerland, Marinus A., Vulpen, Marco van, Wijrdeman, Harm K., & Battermann, Jan J. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. United States. doi:10.1016/j.ijrobp.2005.03.046.
Gellekom, Marion van, Moerland, Marinus A., Vulpen, Marco van, Wijrdeman, Harm K., and Battermann, Jan J. Tue . "Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry". United States. doi:10.1016/j.ijrobp.2005.03.046.
@article{osti_20702192,
title = {Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry},
author = {Gellekom, Marion van and Moerland, Marinus A. and Vulpen, Marco van and Wijrdeman, Harm K. and Battermann, Jan J.},
abstractNote = {Purpose: To investigate changes in quality of life (QoL) after permanent prostate brachytherapy and to correlate these changes with postimplant dosimetry based on magnetic resonance (MR) images. Methods and Materials: For this study, 127 patients with low-stage prostate cancer and treated with brachytherapy received a QoL questionnaire at five time points: before treatment and at 4 weeks, 6 months, 1 year, and 2 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer (EORTC) core questionnaire, the tumor-specific EORTC prostate cancer module, and the American Urological Association symptom index. Postimplant dosimetry was based on registered T1 spin echo transversal, T2 turbo spin echo transversal, and T2 turbo spin echo sagittal MR images and CT images taken 4 weeks after implantation of the iodine-125 seeds. Calculated parameters were prostate volume, prostate volume receiving 100% (V{sub 100}) and 150% (V{sub 150}) dose, dose to 90% of the prostate volume (D{sub 90}), maximum dose in 1-, 2-, and 5-cm{sup 3} rectum volume, distance between prostate and anterior rectum wall, and the maximum dose in 1%, 2%, and 5% urethra volume. Analysis of variance for repeated measures was used for comparison of the means of all variables in the different questionnaires. Linear regression analysis (stepwise) was used to investigate the correlations between QoL parameters and dosimetry parameters. Results: On average, only the QoL at 4 weeks after implant was significantly different from (worse than) the QoL at the other time points. Regression analysis showed a significant correlation between changes in bowel problems and the maximum dose in 2-cm{sup 3} rectum volume, between changes in urinary symptoms and prostate volume, and between changes in urinary problems and the D{sub 90} value of the prostate. Conclusions: The QoL for patients with permanent prostate implants was worse in the first months after treatment but returned to baseline values 1 year after implant. Significant correlations were found between dose distribution and QoL.},
doi = {10.1016/j.ijrobp.2005.03.046},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 3,
volume = 63,
place = {United States},
year = {Tue Nov 01 00:00:00 EST 2005},
month = {Tue Nov 01 00:00:00 EST 2005}
}